Augustana College Augustana Digital Commons

Celebration of Learning

Selenomethionine Protects Mutant Tau N27A Cell from Oxidative Stress and Decreases Phosphorylation of Tau

Madelin LoCicero Augustana College, Rock Island Illinois

Follow this and additional works at: https://digitalcommons.augustana.edu/celebrationoflearning Part of the <u>Education Commons</u>, <u>Medical Neurobiology Commons</u>, and the <u>Medical</u> <u>Pharmacology Commons</u>

Augustana Digital Commons Citation

LoCicero, Madelin. "Selenomethionine Protects Mutant Tau N27A Cell from Oxidative Stress and Decreases Phosphorylation of Tau" (2019). *Celebration of Learning.* https://digitalcommons.augustana.edu/celebrationoflearning/2019/posters/7

This Poster Presentation is brought to you for free and open access by Augustana Digital Commons. It has been accepted for inclusion in Celebration of Learning by an authorized administrator of Augustana Digital Commons. For more information, please contact digitalcommons@augustana.edu.

Selenomethionine Protects Mutant Tau N27A Cell from Oxidative Stress and Decreases Phosphorylation of Tau

Background

 Alzheimer's Disease (AD) is neurodegenerative disease characterized by loss of cells and aggregated tau in the hippocampus (3,4)

Hyperphosphorylated tau causes misfolding proteins and forms neurofibrillary tangles (3)

- Previous research has found that Set-Met decreases the amount of phosphorylated tau at pS404 site within mutant and wild type 3xTg-AD mice (4)
 - Selenium can be toxic dependent on type of cells, and concentration of the selenium (2)

Cellular Model

• N27A cells

- WT and P301L mutant tau mutation (AD linked gene)
- YFP tau cell line

Objectives

Determine the effect selenium methionine has on:

- a. Decreasing hyperphosphorylation of tau
- b. Protecting cells from oxidative stress
- c. Reducing aggregated tau

Madelin LoCicero, Dr. Wenbo Zhou, & Dr. Curt Freed Departments of Medicine, University of Colorado, Anshutz Medical Center, Aurora, Colorado, United States of America, Wartburg West Program



Figure 1a. MTT Assay of N27A (n=6) after H2O2 treatment. Error bars represent standard error of mean. * =p<0.01. Comparing 0uM Set-Met w/ H2O2 and the 20uM Set-Met w/ H2O2, there was a significant increase of cell viability.

Mutant Tau 0uM Set-Met w/o H2O2



Mutant Tau 20uM Set-Met w/H2O2



Figure 2. These cells were treated for 72 hrs. Photos were taken under confocal microscope at 20x magnification. There was a significant change between the 0uM Set-Met w/o H2O2 treatment and 0uM Set-Met and 20uM Set-Met w/ H2O2 treatment. There was no significant difference between the amount of aggregated tau (green signal) between any of the treatment groups.

Western Blot



Figure 3a. Western Blot of WT and mutant tau cell treated with Set-Met after 72 hrs. There was a significant difference between the p-tau and the amount of b-actin in the cells for the mutant tau cells at 20uM.



is the ideal dosage of Set-Met to reduce p-tau.



Conclusion

• Decrease amount of p-tau for mutant tau cell at 20uM • Protect mutant tau cells at 20uM and WT tau cells at 10uM and 20uM from oxidative stress • Set-Met is toxic to cells at 80uM concentration. • Overall, Set-Met could be preventing further phosphorylation to continue and protecting cells from oxidative stress, but are not destroying

aggregated tau

Future Work

• Testing other drugs to see it effect it has on phosphorylation of

CHIR-99021

• Found to inhibit GSK-3A/B

Acknowledgement

This research has been funded by Augie Choice and Wartburg West grant.

Reference

An WF, Germain AR, Bishop JA, et al. Discovery of Potent and Highly Selective Inhibitors of GSK3b. 2012 Apr 16 [Updated 2014 May 13]. In: Probe Reports from the NIH

Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.

. Evangelos Zoidis, Isidoros Seremelis, Nikolaos Kontopoulos, & Georgios Danezis. (2018). Selenium-dependent antioxidant enzymes: Actions and properties of selenoproteins. Basel: MDPI AG. doi:10.3390/antiox7050066 3. Li, C., & Götz, J. (2017). Tau-based therapies in neurodegeneration: Opportunities and challenges. Nature Reviews. Drug Discovery, 16(12), 863-883. doi:10.1038/nrd.2017.155

. Zhang, Z., Wu, Q., Zheng, R., Chen, C., Chen, Y., Liu, Q., . . . Song, G. (2017). Selenomethionine mitigates cognitive decline by targeting both tau hyperphosphorylation and autophagic clearance in an alzheimer's